A rare but life-threatening cardiometabolic problem is known to be associated with serotonin/ dopamine agents that treat psychosis: namely, an association with the sudden occurrence of diabetic ketoacidosis (DKA) or the related condition hyperglycemic hyperosmolar syndrome (HHS). To aid in the prevention of this cardiometabolic problem, the psychopharmacologist's metabolic monitoring tool kit was developed. What does this monitoring tool kit consists of?

A. GALAD levels: GALAD is a biomarker model used to detect hepatocellular carcinoma, not a tool for monitoring metabolic effects of psychotropic medications. It has no clinical relevance to detecting diabetes, dyslipidemia, or hypertension associated with antipsychotic use. B. Fasting glucose: Measuring fasting glucose helps identify insulin resistance or new-onset diabetes caused by atypical antipsychotics. Early detection of hyperglycemia allows for prompt lifestyle or medication adjustments to prevent progression to DKA or HHS. C. Weight/body mass index: Tracking weight and BMI provides a simple but essential measure of metabolic health. Significant weight gain from antipsychotics like olanzapine or clozapine signals increased risk for obesity, diabetes, and cardiovascular complications. D. Fasting triglycerides: Elevated triglyceride levels often accompany insulin resistance and obesity. Monitoring these levels allows clinicians to detect dyslipidemia early and manage cardiovascular risk in patients on psychotropic agents. E. Blood pressure: Regular blood pressure monitoring helps identify antipsychotic-induced hypertension or metabolic syndrome. Sustained increases in blood pressure further elevate the risk of stroke, heart disease, and other cardiometabolic complications.